Spun out of Johns Hopkins, Accelevir Diagnostics is developing new assays for latent HIV. More than 35 million people are living the HIV/AIDS. Current antiretroviral drugs halt, but do not eliminate the virus in people who are infected. Instead, HIV persists in a quiescent, or latent form. New therapeutics are being developed to eliminate this latent virus with the goal of curing the infection: creating innovative assays and technologies to support this therapeutic development effort.
